Skip to main content

Free Content Predictors of sputum culture conversion among patients treated for multidrug-resistant tuberculosis

Download Article:
(PDF 255.13671875 kb)
OBJECTIVE: To identify predictors of initial sputum culture conversion, estimate the usefulness of persistent positive cultures at different time points in predicting treatment failure, and evaluate different definitions of culture conversion for predicting failure among patients with multidrug-resistant tuberculosis (MDR-TB) in five countries, 2000–2004.

METHODS: Predictors of time to conversion were identified using multivariate Cox proportional hazards regression modeling. Receiver operating characteristic curves were plotted to visualize the effect of using different definitions of ‘culture conversion’ on the balance between sensitivity and specificity.

RESULTS: Overall, 1209/1416 (85%) of patients with baseline positive cultures converted in a median of 3.0 months (interquartile range 2.0–5.0). Independent predictors of less likely conversion included baseline positive smear (hazard ratio [HR] 0.60, 95%CI 0.53–0.68), resistance to pyrazinamide (HR 0.82, 95%CI 0.70–0.96), fluoroquinolones (FQs; HR 0.65, 95%CI 0.51–0.83) or thioamide (HR 0.83, 95%CI 0.71–0.96), previous use of FQs (HR 0.71, 95%CI 0.60–0.83), poor outcome of previous anti-tuberculosis treatment (HR 0.69, 95%CI 0.54–0.88) and alcoholism (HR 0.74, 95%CI 0.63–0.87). The maximum combined sensitivity (84%) and specificity (94%) in predicting treatment failure was based on lack of culture conversion at month 9 of treatment, assuming conversion is defined as five consecutive negative cultures.

CONCLUSION: Patients with identified risk factors were less likely to achieve sputum culture conversion during MDR-TB treatment.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: MDR-TB; predictive values; time to culture conversion

Document Type: Research Article

Affiliations: 1: US Centers for Disease Control and Prevention, Atlanta, Georgia, USA 2: Partners In Health (Lima, Peru; Tomsk, Russian Federation; Boston, Massachusetts); Harvard Medical School, Boston, Massachusetts, USA 3: Tartu University Lung Hospital, Tartu, Estonia 4: World Health Organization, Geneva, Switzerland 5: Partners In Health (Lima, Peru; Tomsk, Russian Federation; Boston, Massachusetts) 6: Infectology Center of Latvia, TB and Lung Diseases Clinic, Riga, Latvia 7: Tropical Disease Foundation, Manila, The Philippines 8: National Institute for Health Development, Tallinn, Estonia

Publication date: 2012-10-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more